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1. Introduction
The prevalence of metabolic acidosis increases in Chronic Kidney Disease (CKD) patients ac‐
cording to the fall in glomerular filtration rate (GFR). In early stages of renal dysfunction
acid retention is mainly due to the reduced tubular ammonium (NH4+) secretion. As GFR de‐
clines retention of organic acids (HSO-s4, HPO-4) is also observed. The acid load resultant
from diet and protein catabolism was believed to be the main responsible for acidosis in he‐
modialysis patients, however recent studies have shown an increasingly important role of
hyperchloremia in the genesis of metabolic acidosis and pathophysiological disorders asso‐
ciated with it [1]. This finding was made possible through the use of Stewart´s [2] physico‐
chemical approach for diagnosis and classification of acid base disorders. This new
approach not only enables the identification and classification of acid-base disorders and al‐
lows the quantification of the magnitude of each component to the disorder genesis [3,4].
The current K/DOQI recommendation for the treatment of metabolic acidosis in the patients
on hemodialysis therapy is for maintaining a serum bicarbonate of at least 22 mEq/l [5]. Al‐
though consensus recommendation, the studies on metabolic acidosis in these patients
showed that hemodialysis fail to raise the levels of serum bicarbonate to the desired value.
Santos et al. [6] in a study of metabolic acidosis (HCO-3 < 22 mEq/L) in dialysis patients
found a 90% prevalence of metabolic acidosis. Libório et al. found an average level of serum
bicarbonate in dialysis patients of 18 to 19 mEq/L in their trials [1,7].
The deleterious effects of maintaining metabolic acidosis in this population of individuals
are well known, endocrine disorders and anorexia leading to catabolism of endogenous pro‐
teins and changes in bone mineral metabolism all these contributing to increased morbidity
and mortality in these patients [8].
© 2013 Libório and Leite; licensee InTech. This is an open access article distributed under the terms of the
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CKD related acidosis is associated with several life-threatening conditions. Adequate treat‐
ment of this condition might be associated with better outcomes in the dialysis population
as shown in some studies reporting improvement in nutritional status with oral bicarbonate
supplementation or higher dialysis solution bicarbonate [6]. Data on involvement of chlor‐
ide as cause of acidosis and its implication on acidosis complications are scarce.
In this chapter we intend to approach the importance of metabolic acidosis for dialysis pa‐
tients, discuss the possible pathophysiological mechanisms involved in the genesis of the
acidosis and the consequences that this disorder brings to these individuals, using quantita‐
tive physicochemical approach. We propose to conduct a literature review about the thera‐
peutic alternatives as well as dialysis treatment modalities that could be used for the
correction of this disorder.
2. The acid–base equilibrium: Henderson–Hasselbalch
The Henderson–Hasselbalch equation is still the standard method for interpreting acid–base
equilibrium in clinical practice [9]. It is based in the following equation:
pH  =  pK1΄ +  log HCO 3– /  (Sx PCO2) (1)
This equation describes how plasma CO2 tension, plasma bicarbonate (HCO3–) concentra‐
tion, the apparent dissociation constant for plasma carbonic acid (pK) and the solubility of
CO2 in plasma interact to determine plasma pH. The magnitude of the metabolic acidosis is
generally quantified by the base deficit or base excess, which is defined as the amount of
base (or acid) that must be added to a liter of blood to return the pH to 7.4 at a partial pres‐
sure of carbon dioxide (PCO2) of 40 mmHg [10].
3. Stewart model for acid base disorders
The traditional approach has been criticized as being descriptive rather than mechanistic in
nature and limited in scope and therefore unable to make complete diagnosis in patients
with complex disorders. In contrast, proponents of Stewart’s approach believe it to be mech‐
anistic in nature and comprehensive in scope, able to detect important hidden disorders
[10,11]. The fundamental underpinning of Stewart’s approach is the concept of independent
and dependent variables in acid-base homeostasis. According to Stewart, “Independent var‐
iables in any system are those which can be directly altered from outside the system without
affecting each other” and “...dependent variables in a system can be thought of as internal to
the system. Their values represent the system’s reaction to the externally imposed values of
the independent variables.” [12].
On the basis of Stewart’s definition, H+ and bicarbonate are dependent variables whose con‐
centrations are determined by the three independent variables, Strong Ion Difference (SID),
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PCO2, and total concentration of weak acids (ATOT), mainly composed of albumin and
phosphate [12]. In Stewart’s approach, similar to the traditional approach, respiratory disor‐
ders are those that are due to a primary alteration in PCO2. Metabolic disorders, however,
are due to primary alterations in SID or ATOT and not bicarbonate. By the law of electro‐
neutrality [4]:
( Na +  +  K +  +  Ca 2+  +  Mg 2+ ) –  ( Cl −  +  lactate +  other  strong  anions ) –  ( HCO3−  +  A − ) =  0 (2)
This formula can be rearranged as follows:
( Na +  +  K +  +  Ca 2+  +  Mg 2+ ) –  ( Cl −  +  lactate +  other  strong  anions ) =  HCO3−  +  A − (3)
Therefore,
SID =  ( Na +  +  K +  +  Ca 2+  +  Mg 2+ ) –  ( Cl −  +  lactate +  other  strong  anions ) =  HCO3−  +  A − (4)
Under normal conditions, concentration of lactate and other strong ions is very low and can
be ignored. The formula could therefore be simplified to
SID =  ( Na +  +  K +  +  Ca 2+  +  Mg 2+ ) –  ( Cl − ) =  HCO3−  +  A − (5)
SID therefore can be calculated as the difference between fully dissociated cations and
anions or sum of bicarbonate and A- where A- represents total charges contributed by all
nonbicarbonate buffers, primarily albumin, phosphate, and, in whole blood, hemoglobin.
SID is therefore the same as buffer base concept introduced by Singer and Hasting more
than five decades ago. When an abnormal anion is present, a gap will appear between SID
calculated by the difference between strong ions (the so-called “apparent SID”, SIDa) and
calculated by the addition of bicarbonate and nonbicarbonate buffers (so called “effective
SID” SIDe) (Figure 1). This difference, named strong ion gap (SIG), is a marker for the pres‐
ence of an abnormal anion. Anion gap (AG) is also calculated on the basis of the principal of
electroneutrality as shown as follows [4]:
( total  cations –  total  anions ) =  ( measured  cations +  unmeasured  cations ) –  ( measured  anions + unmeasured  anion ) =  0 (6)
This can be rearranged as:
( measured  cations  –  measured  anions ) =  ( unmeasured  anions  –  unmeasured  cations ) =  AG (7)
In normal state, plasma unmeasured anions reflect charges contributed by the nonbicarbon‐
ate anions (A-), primarily albumin and phosphate. The unmeasured cations are primarily
made up of calcium, magnesium, and, depending on the formula used, potassium. AG, the
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difference between the abnormal and normal (or baseline) AG, represents the amount of ab‐
normal anion(s) present in plasma. SIG, as pointed out already, also represents the amount
of abnormal anion(s) present in plasma and is expected to be mathematically equal to ∆AG
(Figure 1) [4].
This relationship could have been even stronger if ∆AG were calculated in a more precise
manner by using actual baseline values for AG in each patient rather than the mean value of
12 [13]. It should be clear that specific components of Stewart’s formulas, such as SID and
SIG, are conceptually and mathematically closely related to specific components of tradi‐
tional formulas such as bicarbonate, AG, and ∆AG[4].
Figure 1. Relation between Strong Ion Gap (SIG) and ∆AG [4]
4. Classical X Stewart´s approach
One important goal of any method used to analyze acid base disorders is to develop a clini‐
cally useful classification. The traditional approach, using a robust body of empirical obser‐
vations, has developed a classification that contains six primary disorders: Metabolic
acidosis, metabolic alkalosis, acute and chronic respiratory acidosis, and acute and chronic
respiratory alkalosis. Metabolic acidosis can further be classified as anion gap or hyper‐
chloremic acidosis. In addition, by using compensatory formulas as well as ∆AG, the tradi‐
tional approach is capable of diagnosing complex acid-base disorders [14].
In Stewart’s approach, classification of acid base disorders is based on changes in the three
“independent” variables (Table 1) [15]. Respiratory disorders, as in the traditional approach,
are due to a change in PCO2, whereas metabolic disorders are due to alterations in either
SID or ATOT. SID is decreased in metabolic acidosis and increased in metabolic alkalosis. By
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calculating SIG, one can further classify metabolic acidosis. In hyperchloremic metabolic
acidosis, both effective and apparent SID decrease equally, as the increase in chloride is
counterbalanced by an equal decrease in the bicarbonate concentration. SIG therefore re‐
mains at or near zero. In AG metabolic acidosis, apparent SID does not change (as chloride
concentration is unchanged), but effective SID decreases (as a result of a decrease in bicar‐
bonate concentration) and SIG therefore becomes positive [15]. One major departure from
the traditional approach is classification of acid-base disorders as a result of alteration in
ATOT. ATOT, representing all nonbicarbonate buffers pairs (HA + A-), is made up of charg‐
es contributed primarily by serum proteins (mainly albumin) with phosphate and other buf‐
fers playing a minor role. On the basis of this classification, an increase in serum protein





Water excess/deficit ↓SID, ↓ [Na] ↑SID, ↑[Na]
Imbalance of Strong anions
Chloride excess/deficit ↓SID, ↑[Cl] ↑SID, ↓[Cl]
Unidentified anion excess ↓SID, SIG "/> 0
Nonvolatile weak acids
Serum albumin ↑[Alb] ↓[Alb]
Inorganic phosphate ↑[Pi] ↓[Pi]
Table 1. Classification of acid-base disturbances according to Stewart´s approach [4]
5. Pathophysiology of acidosis in CKD
Classical uremic acidosis is characterized by a reduced rate of NH4+ production and excre‐
tion because of cumulative and significant loss of renal mass [17]. Usually, acidosis does not
occur until a major portion of the total functional nephron population (>75%) has been de‐
stroyed, because of the ability of surviving nephrons to increase ammonia genesis. Howev‐
er, there is a decrease in total renal ammonia excretion as renal mass is reduced to a level at
which the GFR is 20 mL/min or less. PO43– balance is maintained as a result of both hyper‐
parathyroidism, which decreases proximal PO43–absorption, and an increase in plasma PO43–
as GFR declines. In advanced renal insufficiency, including hemodialysis patients, the hy‐
perchloremic acidosis discussed earlier converts to a typical high AG acidosis. Poor filtra‐
tion plus continued reabsorption of poorly identified uremic organic anions resulting from
diet and body metabolism contributes to the pathogenesis of this metabolic disturbance [17].
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Libórioet al. [1] showed when using Stewart´s approach to acid–base disorders in mainte‐
nance hemodialysis that unmeasured anions are an important cause of acidosis in this popu‐
lation, contributing to more than 40% of reduction in serum bicarbonate. A surprising
finding was the role of hyperchloremia in acidosis etiology, which had a similar quantitative
effect in acidosis. Recently, a study carried out in nondialysis chronic renal failure patients
disclosed the main role of hyperchloremia in acidosis [18]; however, the acidosis composi‐
tion in the dialysis population is still largely unknown.
The lack of quantitative analysis has led major textbooks to the assumption that the acidosis
in these patients is due to the accumulation of unmeasured anions only, leading to high
anion gap acidosis. Rocktaeschelet al. [19] showed in acute renal failure, acidosis also has
complex and multiple etiologies in maintenance hemodialysis.
Sevelamer hydrochloride is a known cause of acidosis in hemodialysis due to the load of hy‐
drochloric acid (each 800 mg tablet of sevelamer hydrochloride leads to an acid load equiva‐
lent to 4 mEq hydrochloric acid) [20].Another potential culprit in the cause of
hyperchloremia is the chloride levels in the dialysate bath. In a literature review,15 consider‐
able variations were found in dialysate chloride levels: from 90 to 125 mEq/l. The elevation
in chloride is accompanied by a reduction in dialysate SID. Considering this fact, the maxi‐
mum level of dialysate chloride must be 105 mEq/l, allowing the dialysate SID to increase
up to 40 mEq/l, a value similar to that of plasma [7].
Acidosis in maintenance hemodialysis has multiple etiologies. Unmeasured anions and hy‐
perchloremia are the main components, and hyperphosphatemia has a minor effect. Hyper‐
chloremia cannot be attributed to sevelamer hydrochloride therapy alone, and we speculate
that high levels of chloride in dialysate constitute a potential culprit. Additional studies as‐
sessing the relationship between the nature of acidosis and its detrimental effects on bone,
inflammation, and nutrition are warranted [1].
6. Consequences of metabolic acidosis
6.1. Exacerbation of bone disease and impaired growth in children
Studies indicate that metabolic acidosis can be a contributory factor to the development or
exacerbation of bone disease in both adults and children and that it can impair growth in
children with or without CKD. Direct effects of an acidic milieu on bone and indirect effects
mediated by changes in PTH levels and/or its actions or vitamin D levels appear to contrib‐
ute to these pathological effects [21].
Bone disease in CKD is mainly due to alterations in parathyroid hormone (PTH) and vita‐
min D levels. Certain toxins, such as aluminum may play a role [22]. However there is a sub‐
stantial amount of data relating chronic metabolic acidosis as an additional important factor
[23,24]. In vitro and in vivo studies have demonstrated that prolonged metabolic acidosis
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can directly stimulate osteoclast-mediated bone resorption and inhibit osteoblast mediated
bone formation [24-27]. Some animal and human studies have shown that metabolic acido‐
sis can reduce vitamin D levels and stimulate PTH secretion. Metabolic acidosis also attenu‐
ates the cellular response to PTH, as measured by cAMP accumulation in rat tissues. The
actions of the calcium sensing receptor might also be attenuated by a decrease in extracellu‐
lar pH, perhaps contributing to an increase in PTH levels [21]. Chloride might also be relat‐
ed to higher PTH levels and worsening bone disease. Using Stewart´s physicochemical
approach Liborio et al. [28] found a higher PTH levels in hemodialysis patients with higher
chloride serum concentration and a significant relationship between chloride, PTH levels
and serum markers of mineral bone disease.
In adult patients on chronic maintenance hemodialysis, amelioration of the acidosis by rais‐
ing the dialysate base concentration was found to attenuate the rise in PTH, reduce bone re‐
sorption, and improve bone formation. In another study in dialysis patients, correction of
the acidosis restored the normal suppression of PTH secretion in response to infused calci‐
um [21]. Although controlled studies of the impact of correction of metabolic acidosis alone
on the growth in children with CKD are not available, metabolic acidosis is considered to be
a contributory factor to short stature in children with CKD prior to or after initiation of
chronic maintenance dialysis. It´s recommended that it be corrected prior to the initiation of
growth hormone therapy [29].
Data about chloride and SID changing in dialysis bath and bone disease outcomes are still
lacking. New studies in dialysis population assessing the long term effect this measure
might influence in the amelioration of bone disease must emerge.
6.2. Increased muscle wasting
Muscle wasting is increased in CKD. This is not only due nutritional deprivation or expo‐
sure to a uremic milieu. Metabolic acidosis in CKD stimulates muscle wasting and may im‐
pair growth in children [30].
The increased protein degradation was due to the increased transcription of genes encoding
proteins of the ATP-dependent ubiquitin–proteasome pathway, resulting in increased activi‐
ty of the ATP-dependent ubiquitin–proteasome system (UPS) [30]. Of interest, activation of
muscle protein degradation requires endogenous glucorticoids [21]. Recent studies have
identified the dependency on glucocorticoids to increase muscle protein wasting as a non-
genomic mechanism by which the glucocorticoid receptor sequesters phosphatidylinosi‐
tol-3-kinase to interrupt insulin–IGF-1 signaling [31]. Several conditions including CKD and
metabolic acidosis appear to be related to the activation of the UPS. In several studies, ameli‐
oration of metabolic acidosis by the provision of base to patients with CKD before or after
initiation of maintenance dialysis decreased the rate of protein degradation and urea genera‐
tion, resulting in improved protein balance and increased muscle mass [30].
Similar to bone disease, some evidence suggests that a detectable fall in serum [HCO3−] may
not be necessary to stimulate muscle degradation. [21]
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6.3. Reduced albumin synthesis
Hypoalbuminemia is the most common marker of protein-energy wasting in dialysis pa‐
tients and has strong association with increased morbidity and mortality. Hypoalbumine‐
mia  is  associated  with  development  and  recurrent  cardiac  failure  in  hemodialysis
patients [32].
Experimental induction of metabolic acidosis in normal humans for at least 7 days has in
some studies caused a reduction in albumin synthesis, thereby predisposing the individual
to the development of hypoalbuminemia [33,34]. Indeed, analysis of more than 1500 patients
> 20 years of age who participated in the NHANES III study revealed that the age-adjusted
odds ratio of serum [HCO3−] for hypoalbuminemia rose from 1.0 for serum [HCO3−] > 28
mEq/l to 1.54 for serum [HCO3−] ≤22 mEq/l [35]. Furthermore, in two studies of adult pa‐
tients with CKD either prior to or after initiation of chronic maintenance dialysis, improve‐
ment of the metabolic acidosis by the provision of base caused the serum albumin
concentration to rise and protein catabolic rate to fall [36,37].
Reduced protein synthesis, increased protein breakdown, and enhanced amino acid oxida‐
tion have all been suggested as factors contributing to a reduced serum albumin concentra‐
tion with metabolic acidosis. A decrease in protein intake might also play a role, although in
one study in which dietary intake was examined, no difference in protein intake was found
in patients with CKD before or after correction of the acidosis [21].
6.4. Accelerating the progression of CKD
Studies in humans have supported the potential role of metabolic acidosis in the progression
of CKD. In a large cohort of patients with CKD followed at a single medical center, a serum
[HCO3−] of <22 mEq/l was associated with a 54% increased hazard of progression of CKD
when compared with a serum [HCO3−] of 25–26 mEq/L [38]. In two separate studies, one in
patients with hypertensive renal disease [39]and another in patients with CKD of diverse
etiology [40], the administration of base slowed the progression of CKD. In the latter study,
the rate of decline in GFR in those given bicarbonate was less than half that in the control
group. Moreover, the bicarbonate group was less likely to experience a rapid decline in GFR
or develop end-stage renal disease [21].
Three mechanisms have been postulated to explain the acceleration of progression of CKD
in response to metabolic acidosis. First, it has been suggested that the increase in renal me‐
dullary ammonia concentration resulting from the stimulation of ammonia production by
metabolic acidosis activates the alternative complement pathway and causes progressive tu‐
bulointerstitial injury [41]. Second, it has been suggested that new bicarbonate synthesized
by the kidney in response to acidosis alkalinizes the interstitium and encourages precipita‐
tion of calcium in the kidney [42]. Finally, evidence in both animals and humans has been
accrued to suggest that increased endothelin production may mediate the tubulointerstitial
injury and decline in GFR noted with the metabolic acidosis of CKD [43].
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6.5. Impaired glucose homeostasis
Studies in patients with CKD demonstrated impaired glucose tolerance and insulin resist‐
ance, both prior to and after the initiation of chronic maintenance dialysis. The effect of ure‐
mia on insulin resistance appeared to be related, in part, to metabolic acidosis, because the
administration of base to stable hemodialysis patients improved, although it did not nor‐
malize, insulin sensitivity. The insulin resistance and glucose intolerance of uremia per se
are generally not severe, but it is possible that they contribute to the development of other
clinical abnormalities [21].
6.6. Accumulation of β2-microglobulin
The accumulation of β2-microglobulin in individuals with CKD contributes to the develop‐
ment of amyloidosis. Amyloid infiltration can cause the carpal tunnel syndrome, bone cysts
and, possibly, cardiomyopathy [44]. This accumulation of β2-microglobulin is primarily re‐
lated to the number of years on dialysis, which has been interpreted as suggesting that the
predilection to amyloidosis is due to reduced excretion of β2-microglobulin and, in the case
of hemodialysis, also to chronic exposure of blood to the dialysis membrane [44].
Metabolic acidosis has been suggested as a possible additional factor in promoting β2-mi‐
croglobulin accumulation. First, there is an inverse correlation between serum [HCO3−] and
β2-microglobulin levels in patients with CKD. Furthermore, β2-microglobulin concentra‐
tions have been found to be higher in patients dialyzed with acetate who have a lower se‐
rum [HCO3−] than those dialyzed with bicarbonate [44].
6.7. Abnormal thyroid function
Individuals with uremia have low basal metabolic rates. This could be related in part to the
associated metabolic acidosis affecting thyroid hormone levels, since ammonium chloride-
induced metabolic acidosis has been found to be associated with reduced triiodothyronine
(T3) and thyroxine (T4) and elevated thyroid-stimulating hormone levels [21]. Correction of
metabolic acidosis in patients with CKD causes T3 levels to rise towards normal [45].
6.8. Stimulation of inflammation
Exposure of macrophages to an acidic environment leads to the increased production of tu‐
mor necrosis factor α (TNFα) [46]. In one study, the correction of metabolic acidosis in a
small number of patients maintained on chronic ambulatory peritoneal dialysis was associ‐
ated with a reduction in TNFα levels [21]. Thus, it has been suggested that metabolic acido‐
sis is associated with the stimulation of inflammation and, therefore, that it represents a
chronic inflammatory state. However, no significant difference was observed in the serum
levels of C-reactive protein and interleukin-6 (two biomarkers of inflammation) among three
separate groups of dialysis patients with a mean serum [HCO3−] of 19.2, 24.4, and 27.5
mEq/L, respectively [47].
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6.9. Development or exacerbation of cardiac disease and increase in mortality
Low serum bicarbonate level is related to higher mortality in CKD patients both prior [48] to
and after initiation of chronic maintenance dialysis [21]. A retrospective analysis of laborato‐
ry data obtained from more than 12,000 hemodialysis patients showed an increased risk of
death in patients with a serum [HCO3−] <15–17 mEq/L [49]. Also, patients with CKD not on
dialysis had a greater risk of death when their serum [HCO3−] was <22 mEq/L [50]. Navanee‐
thanet al. [48]found a higher mortality rate in the group of patients with lower serum bicar‐
bonate ([HCO3−] < 23 mEq/L) level in a trial of 41.445 stage 3 and 4 CKD patients. An
interesting finding of this trial was that higher level ([HCO3−] > 32 mEq/L) was also associat‐
ed with poor outcome and higher mortality rate. The DOPPS study [51] showed better out‐
comes in maintenance hemodialysis patients with midweek bicarbonate serum level of 21,1
to 22 mEq/L. In this study both low ([HCO3−] < 17 mEq/L) and higher (>24 mEq/L) were re‐
lated to higher hospitalization and mortality rate. These data point to the importance of a
strict control of metabolic acid base disturbances in CKD patients and the harmful effect of
overcorrection of acidosis.
Cardiovascular disease is the most common cause of death in patients with CKD. There are
strong evidence that inflammation plays an important role in the genesis and progression of
atherosclerotic heart disease. As discussed earlier in this text acidosis is a chronic inflamma‐
tory state and it is reasonable to speculate that metabolic acidosis could be related to in‐
creased prevalence or severity of cardiovascular disease [21].
6.10. Renal replacement therapy and liver failure
Anticoagulation with heparin might be a problem in patients with increased bleeding risk
specially critically ill patients and cirrhotic patients requiring continuous renal replacement
therapy (CRRT). There is increasing evidence questioning the safety of heparin in such pa‐
tients and there are accumulating data on a potential better alternative, regional anticoagula‐
tion with citrate. Sodium citrate administered before the filter inhibits the generation of
thrombin. For anticoagulation the citrate dose is adjusted to blood flow to attain low ionized
calcium (< 0,4 mmol/l ) concentration in the filter, the lower the calcium concentration the
higher the degree of anticoagulation. Citrate is partially removed by the filter and the re‐
maining amount is metabolized in citric acid cycle predominantly in the liver. The chelated
calcium is than released and the lost calcium is replaced after filter. The systemic coagula‐
tion is unaffected [52].
Buffer strength of citrate depends on the proportion of strong cations in the fluid counter‐
balancing citrate concentration. Assuming the citrate is completely metabolized, one micro‐
mole of trisodium citrate provides the buffer as 3 mmol sodium bicarbonate. The Stewart
Concept provides an easier way to understand the buffering effect of citrate: after metabo‐
lized in the liver the remaining sodium increases serum SID. Increased SID produces alkalo‐
sis. Sodium citrate has a SID of zero until citrate is metabolized, so in conditions where
citrate metabolism is grossly impaired, such as severe liver dysfunction the citrate alkaliniz‐
ing effect might be compromised. Citrate accumulation decreases the SID leading to a meta‐
bolic acidosis [52]. For this reason anticoagulation free or low heparin regimens have been
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used for patients with severe liver dysfunction requiring continuous renal replacement ther‐
apy. This strategy reduces bleeding risk however lowers the procedure efficiency and thefil‐
ter patency.
Recent studies have emerged showing protocol using sodium citrate as a safe alternative for
anticoagulation even in patients with liver dysfunction. In a prospective randomized open
label crossover trial of regional citrate anticoagulation vs. anticoagulation free liver dialysis
by the Molecular Adsorbents Recirculating System (MARS) Meijers et al. [53] demonstrated
that citrate anticoagulation significantly increased the likelihood of completed MARS treat‐
ment (P = 0,04), higher bilirubin reduction ratio when citrate was applied and improvement
in systemic ph levels. In this study, systemic ionized calcium concentrations were signifi‐
cantly reduced during citrate anticoagulation but remained within a safe range even using
standard protocol for extracorporeal calcium levels. There were no major adverse events in
the citrate group. Other study in early post liver transplantation patients requiring CRRT
showed efficacy and safety of regional citrate anticoagulation without severe decrease in cal‐
cium concentration and acidosis [54]. Another study applied anticoagulation with sodium
citrate in patients with severely impaired liver dysfunction (mean Child-Pugh score: 10,5)
under renal replacement therapy with sustained low efficiency dialysis (SLED) after repeat‐
ed filter clotting (filter lifetime < 2h) under heparin free or low dose heparin therapy. The
dialysis time with citrate anticoagulation was 17,3 h, filter lifetime increased to 23,3 h. No
major bleeding episodes related to dialysis therapy were observed, total calcium, ionized
calcium, calcium gap, electrolytes and base excess were maintened at stable levels during
therapy and thereafter. There were no significant hypotensive episodes and norepinephrine
dose was reduced during therapy. This protocol used lower citrate infusion rate with higher
post-filter ionized calcium levels and absence of routine calcium supplementation at venous
line and the use of high-flux dialyser for reducing the risk of accumulating calcium citrate
complexes [55].
These data show increasing evidence that citrate might be used for anticoagulation even in
patients with impaired liver function. However clinicians should be alert when using this
strategy, measuring the citrate levels and use of high-flux dialyser must be applied for war‐
ranting safety of maintaining low citrate concentrations. Data showing safety of citrate re‐
gional anticoagulation and recommendation of its use in patients with liver impairment
under CRRT are scarce and don´t warranty recommendation of its application for this mo‐
dality of treatment.
7. Treatment of metabolic acidosis in hemodialysis patients
The standard recommendation for correction of metabolic acidosis in CKD patients is for
reaching a bicarbonate level at least 22 mEq/L in dialytic and conservative management pa‐
tients [5]. Reaching this level may be a challenging schedule [1,6,7]. Current dialysate base
standards appear to be somewhat arbitrarily chosen. Standard concentrations of bicarbonate
in dialysates (33–35 mEq/L) do not completely correct the acidosis [56].
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Alkali therapy has been shown to retard the progression of CKD in patients with reduced
GFR not in dialysis therapy [57]. Benefits of correcting this disturbance in hemodialysis pa‐
tients have already been reported in this chapter.
Routine measuring bicarbonate serum levels and the application of one of the following
strategies might be of utility for maintaining bicarbonate target concentration and improv‐
ing outcomes.
7.1. Oral supplementation
In CKD patients in conservative management acidosis should be treated by administering
base in the form of oral bicarbonate or organic anions that are metabolized to bicarbonate
such as citrate. Once serum bicarbonate reaches the desired level, the amount of base admin‐
istered can be reduced to the minimal necessary to maintain this level [21]. A Systematic re‐
view on treatment of metabolic acidosis in non-dialysis patients showed improvement in
kidney function, which may afford a long term benefit in slowing the progression of CKD
[57]. Papadoyannakis et al. [58]found that ingestion of sodium bicarbonate corrects metabol‐
ic acidosis and increases appetite and body mass of the end-stage renal failure patients.
In dialysis patients oral administration of calcium carbonate at a dosage of 3–6 g/daily raises
pre-dialysis plasma bicarbonate [59]. Calcium carbonate induces positive nitrogen balance
due to correction of metabolic acidosis. Furthermore, calcium carbonate serves as a phos‐
phate binder [60]. Instead of ingestion of the bicarbonate, calcium salts of organic acids
could also be used as phosphate binders, i.e. acetate, citrate, gluconate or ketogluterate,
which all could be metabolized into bicarbonate [61].
7.2. Bicarbonate based dialysis solution
Whichever dialysis therapy is used, there is a similar need for correcting the acid-base bal‐
ance. The most important tool for this aim is the buffer in the dialysis fluid. Bicarbonate dial‐
ysis achieves much better hemodialysis stability [62]. Based on clinical and experimental
studies, different side effects of hemodialysis treatment have been attributed to acetate, such
as nausea, vomiting, headache, muscle cramps, hypotension, hemodynamic instability and
increased cytokine release [63,64]. In contrast to acetate dialysis, bicarbonate dialysis does
not interfere with gluconeogenesis and lipid synthesis [65]. The buffer source in all modern
versions of these therapies should be bicarbonate. Bicarbonate is a physiological buffer,
therefore in bicarbonate dialysis, plasma bicarbonate concentration and blood pH progres‐
sively increase during the dialysis session[65].
7.3. Higher bicarbonate in dialysate
Rising bicarbonate level in dialysate is effective in correcting metabolic acidosis. This correc‐
tion is associated with improvement in CKD related anorexia and influencing the nutritional
status [6]. Choosing dialysate bicarbonate level might be challenging. Some observations
confirmed that dialysate bicarbonate concentrations of 40 mEq/L appear safe and well toler‐
ated [66,67]. Oettinger and Oliver [68] demonstrated that high-bicarbonate dialysate (42
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mEq/L) corrects pre-dialysis acidosis in 75% of hemodialysis patients without causing pro‐
gressive alkalemia, hypoxia, or hypercarbia and that pre-dialysis BUN, calcium, ionized cal‐
cium and phosphorus are unaffected by high-bicarbonate dialysate. Williams et al. [69]
demonstrated that bicarbonate dialysate concentrations of 40 mEq/L were safe, well tolerat‐
ed and produced better control of acidosis (significantly higher pre-dialysis arterial plasma
pH values as pre-dialysis serum total CO2), with an increase in triceps skinfold thickness,
compared to a bicarbonate concentration of 30 mEq/L. The amount of base transferred to the
patient during dialysis depends on the patient’s needs. Agroyannis et al. [70] showed a sig‐
nificant correlation between interdialytic weight gain and the values of pre-hemodialysis
blood pH and bicarbonate, suggesting an important role of the interdialytic weight gain on
acid-base equilibrium of uremic patients undergoing hemodialysis.
There is no doubt that individualized bicarbonate concentration is necessary for hemodialy‐
sis patients. Therefore, the choice of dialysate bicarbonate concentration should also be pre‐
dicted on the basis of the patient’s determinants (hydrogen generation, bicarbonate
distribution space) and technique-related factors (membrane permeability, ultrafiltration
rate, blood and dialysate flow) [71]. This can be achieved by new dialysis machines and by
bicarbonate profiling.
7.4. Changing SID – The physicochemical approach
The base supply by dialysis does not seem to represent the main mechanism for acid-base
correction by dialysis. Using Stewart´s physicochemical approach Liborio et al. [1], showed
in that chloride might play a pivotal role in pathogenesis of metabolic acidosis in hemodial‐
ysis patients. Other study found a better correction in bicarbonate levels after dialysis with a
chloride level of 107 mEq/L rather than 111 mEq/L [7]. Such correction in serum bicarbonate
might be possible due to elevation in plasma SID by exposing plasma to higher SID in dialy‐
sis solution. However although not expected, correction of metabolic acidosis in this study
was mainly due to reduction of unmeasured anions, represented in Stewart´s model by SIG.
This unexpected reduction in unmeasured anions can be explained by Gibbs Donnan equili‐
brium. The reduction in serum chloride during the post-dialysis period can facilitate redis‐
tribution from the intracellular or interstitial compartment, this decrease in intracellular
chloride can improve the intracellular capacity of buffering other negative charges, reducing
plasma unmeasured anions. Another possible explanation may be found in the dialysate
compartment. It has been suggested that a higher dialysate chloride concentration, through
Gibbs-Donnan equilibrium across the dialyzer membrane, partially prevents an adequate
clearance of unmeasured anions due to a charge effect, i.e., electric repulsion of a negative
charge. Moreover, based on this principle, it is not possible to exclude that an improvement
in bicarbonate diffusion might have been the result of using a lower dialysate chloride con‐
centration [7].
Diet, intestine, bone and intermediate metabolism could play a pivotal role in the acid-base
status of uremic patients. Probably, more attention needs to be paid to the possible noxious
effect of overcorrection of acidosis. Rapid correction of acidosis by bicarbonate dialysis may
cause drowsiness, unconsciousness, hypokalemia and cardiac arrhythmia [72].




Metabolic acidosis is a detrimental condition both for CKD patients on hemodialysis thera‐
py or conservative management. Several adverse effects of maintenance of an acidic state
come with the falling in GFR and developing and worsing of acidosis. Several strategies
have been employed for correction of that disturbance as listed before, some need more re‐
searches for finding consistent results of the benefits of such strategies. Stewart´s approach
brought new perspectives for understanding and treating this disturbance. Studies validat‐
ing changing SID, chloride or other components of the dialysate bath are still need.
Attention must be paid for the metabolic alkalosis in this population as a result of overcor‐
rection or overtreatment of acidosis. This one brings deleterious effects like metabolic acido‐
sis. How metabolic alkalosis impairs survival in CKD is still unknow, new researches are
need in this field.
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